Company profile: Genelabs Technologies
1.1 - Company Overview
Company description
- Provider of biopharmaceutical R&D focused on discovering and developing therapies for infectious diseases, offering drug discovery services and medications including Morphine for severe pain, Atomoxetine (Strattera) for ADHD, Finasteride (Propecia) for male pattern hair loss, and Valacyclovir (Valtrex) for herpes and shingles.
Products and services
- Drug Discovery: Architects infectious disease therapeutics using high-throughput screening, medicinal chemistry, and computer-aided drug design to identify new candidate medications and optimize leads for treatment
- Valacyclovir (Valtrex): Supplies antiviral treatment for herpes and shingles, and treats outbreaks of genital herpes in infectious disease management
- Morphine: Supplies opioid analgesic for severe pain, available in various formulations and derivatives for different medical applications in pain management
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Genelabs Technologies
Mpex Pharma
HQ: United States
Website
- Description: Provider of biopharmaceutical development of new therapies to combat antibiotic resistance, with a particular focus on gram-negative organisms. The company's internal pipeline combines proprietary formulations, PK/PD strategies and novel potentiating agents.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mpex Pharma company profile →
DNAe
HQ: United Kingdom
Website
- Description: Provider of rapid near-patient molecular diagnostics, offering the LiDia-SEQ platform for direct-from-specimen DNA sequencing on a microchip; BSI/AMR test detecting bloodstream infections and antimicrobial resistance from whole blood; a sample preparation system extracting pathogens via immunomagnetic beads; semiconductor sequencing technology; and an oncology program for tumor DNA monitoring.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DNAe company profile →
Stat-Dx
HQ: Spain
Website
- Description: Provider of near-patient testing products for healthcare professionals, primarily for short turnaround time applications and critical care.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Stat-Dx company profile →
Bugworks Research
HQ: India
Website
- Description: Provider of drug discovery focused on combating antimicrobial resistance (AMR) and small molecule cancer therapeutics, including BWC2094 targeting the adenosine pathway (CRC, NSCLC, TNBC, pancreas, prostate, RCC, HNSCC); ATM/DNA-PK dual inhibitors (BWC5036/BWC5089); BWC5044/BWC5077, BWC4496; spliceosome modulators/DNA damage agents; and ADC payload opportunities.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bugworks Research company profile →
Cerexa
HQ: United States
Website
- Description: Provider of novel anti-infective therapies for serious and life-threatening infections; develops a portfolio of treatments including Ceftaroline Acetate/Ceftaroline, an injectable cephalosporin used for bacterial infections.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cerexa company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Genelabs Technologies
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Genelabs Technologies
2.2 - Growth funds investing in similar companies to Genelabs Technologies
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Genelabs Technologies
4.2 - Public trading comparable groups for Genelabs Technologies
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →